evolcSign inStart free
Menu

Enara Bio

Cancer immunotherapies for patients with solid tumors, developed using dark-antigen discovery and T-cell engager platforms

Oxford, United KingdomFounded 2016enarabio.comWebsite technologies

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-10-27

About Enara Bio

Enara Bio discovers and validates cancer-specific Dark Antigen targets derived from genomic regions previously considered non-coding. It is developing bispecific T-cell engagers for solid tumors, including a lead program targeting DARKFOX.

The company collaborates with pharmaceutical companies and academic institutions, including Boehringer Ingelheim and the Francis Crick Institute. Its investors include RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors.

Founded in 2016, Enara Bio is headquartered in Oxford, United Kingdom.

Product: EDAPT discovers and validates Dark Antigen targets, while EnTiCE supports development of bispecific T-cell engagers for solid tumors.

Jobs at Enara Bio

No open positions listed right now.

Leadership

More biotech & pharma companies

  • Ensocell

    AI-driven discovery of precision therapies for fibrotic and autoimmune diseases using human biological data
    United KingdomBiotech & pharma1 open job
    New on Evolc

  • Enterobiotix

    Clinical-stage microbiome therapeutics developing the oral drug EBX-102-02 for irritable bowel syndrome and related gut and liver diseases
    Bellshill, United KingdomBiotech & pharmaFounded 2017
    New on Evolc

  • Enterprise Therapeutics

    Develops investigational medicines for people with cystic fibrosis and other respiratory diseases
    Brighton, United KingdomBiotech & pharmaFounded 2014
    New on Evolc

  • Epidarex Exeed

    Seeds early-stage life science ventures by developing breakthrough therapeutic research into investable assets
    Edinburgh, United KingdomBiotech & pharmaFounded 2019
    New on Evolc

  • Epitopea

    Develops off-the-shelf RNA cancer immunotherapies for patients with difficult-to-treat cancers
    Cambridge, United KingdomBiotech & pharmaFounded 2021
    New on Evolc

  • Epsilogen

    Develops antibody-based cancer treatments, including a clinical candidate for ovarian cancer
    London, United KingdomBiotech & pharmaFounded 2016
    New on Evolc

All biotech & pharma companies →

Website technologies

Older, unverified list. Detection dates and supporting evidence are not yet available.

  • Google Universal Analytics
  • Google reCAPTCHA
  • nginx